Co-investment programs have become standard furniture in GP-LP relationships, but their presence on a term sheet resolves nothing. The same mechanism that genuinely extends LP economics can, with minor structural adjustments, serve primarily to reduce GP risk concentration while preserving management fee revenue. The difference lives in the details most LPs skim.

What Genuine Alignment Looks Like

A co-investment offer with real alignment typically surfaces on deals where the GP has already committed meaningful fund capital and is offering pro-rata participation at the same entry price, with no incremental management fee and a reduced or zero carry tier on the co-invest sleeve. The GP is, in effect, inviting the LP to sit alongside them on a position they already believe in enough to size from the main fund.

The structural signals worth tracking: the co-invest closing timeline mirrors the fund deal timeline (not a recycled secondary offering), the co-invest vehicle uses the same valuation methodology as the main fund, and the GP’s own balance sheet has meaningful exposure to the same asset. When those three conditions hold simultaneously, the offer is generally what it claims to be.

Where the Structure Starts Working Against You

The problematic variant tends to appear in one of two forms. The first is the “overflow” co-invest, where the GP has sourced a deal too large for the fund’s concentration limits and is effectively syndicating the excess to LPs who bear deal-specific risk without the portfolio diversification the fund structure provides. The management fee on the co-invest sleeve softens the GP’s economics on a deal they couldn’t fully absorb themselves.

The second form is subtler: co-invest rights offered predominantly on assets the GP has already marked up internally, often late in a fund’s cycle when the GP benefits from LP capital validating a higher carrying value. The LP gets exposure to an asset with compressed upside and the GP gets a supportive data point for the next fundraise. Neither fact will appear in the offer memo.

• No incremental management fee: Any co-invest sleeve charging a full or partial management fee deserves extra scrutiny on the rationale.
• Entry timing: Co-invests offered more than six months after initial fund deployment into the same asset warrant questions about what changed in the interim.
• GP balance sheet exposure: GPs with personal capital or GP commitment in the co-invest sleeve have a different incentive structure than those offering pure third-party syndication.
• Information rights: Co-invest vehicles that lack independent board observation or information rights create asymmetric information between the GP and co-investing LP.

The Negotiating Leverage Most LPs Leave on the Table

LPs with sufficient commitment size can negotiate co-investment rights with advance notice minimums, typically 10 to 15 business days, which meaningfully changes the analytical process available before a closing deadline. Compressed timelines on co-invests are not accidental; they limit the LP’s ability to conduct independent diligence on an asset the GP has been studying for months.

A right of first refusal on co-invest allocations, tied to pro-rata fund commitment, is also a negotiable term that larger LPs frequently do not request. GPs with strong deal flow typically prefer a small group of reliable co-invest partners over a broad syndication process, which creates more room for structural conversation than most LPs assume.

The Operator Read

Co-investment programs are worth having in an LP agreement, but the value is entirely structural, not cosmetic. The question is not whether the right exists but under what conditions it activates, on what terms, and on which vintage of assets. Operators who treat co-invest rights as a negotiating outcome rather than a relationship courtesy tend to find the economics considerably more interesting when the opportunity actually arrives.